INTRODUCTION
Many human cancers as well as many developmental abnormalities are characterised by the presence of genomic DNA copy number changes. In cancer, genes detrimental to tumour growth (eg tumour suppressor genes) are likely to be contained in regions of decreased DNA copy number, while genes important for tumour growth or development (eg oncogenes) are likely to be contained in regions of increased DNA copy number. Over the past decade, comparative genomic hybridisation (CGH) has been used extensively to map DNA copy number changes to a chromosomal position. CGH was first described in 1992 by Kallioniemi et al. 1 In this technology, differentially labelled and denatured genomic DNA pools are simultaneously hybridised to immobilised and denatured chromosome metaphase spreads ( Figure  1 ). After hybridisation, the fluorescence ratio is measured along the axis of each chromosome, creating a genome-wide profile of the relative copy number in the DNA pools. Usually, test genomic DNA (eg tumour genomic DNA) labelled with one fluorochrome and reference genomic DNA (eg normal genomic DNA) labelled with a different fluorochrome are simultaneously hybridised in the presence of high concentrations of unlabelled Cot-1 DNA, which blocks repetitive DNA sequences.
The main advantage of CGH is that the whole genome can be interrogated for DNA copy number in a single experiment. After analysing large numbers of tumours, recurrent regions of copy number alteration can be defined, thereby identifying the region(s) containing genes involved in cancer development. One main disadvantage of chromosome CGH is the limited resolution at which DNA copy number aberrations can be detected. Typically, the limit for detection of DNA copy number loss is approximately 10 Mb, but it can be less for copy number gains depending on the size of the involved region and level of copy number increase. Application of statistical methods that correct for variation along the CGH profile can also provide improved resolution. 2, 3 The development of microarray technology opened a way to overcome many of the limitations of CGH, because the metaphase spreads could be replaced by mapped DNA clones, thereby providing a means to link aberrations directly to the genome sequence. Several approaches have been undertaken to implement array-based CGH. The different approaches can be categorised based on the properties of the DNA deposited on the substrate and on the properties of the genomes to be interrogated by the arrays. This review will summarise different approaches towards microarray CGH and their advantages and disadvantages.
MICROARRAY CGH
Microarrays are usually created by highprecision robotics, which deposit and immobilise small amounts of DNA (spots) closely spaced on a substrate (usually a glass surface) in a regular and/or ordered fashion. Typically for microarray CGH, one simultaneously hybridises differentially labelled genomic DNA pools to each array. The DNAs are labelled in vitro by random priming to incorporate fluorescently labelled nucleotides, usually Cy3 and Cy5. After hybridisation, digital images of each of the hybridised fluorochromes can be obtained using various types of imaging systems.
The use of mapped DNA clones for array CGH allows direct linkage of aberrations and genomic sequence Figure 1 : Overview of conventional and array-based comparative genomic hybridisation (CGH). Test genomic DNA is labelled with one fluorochrome (eg Cy3) and reference genomic DNA is labelled with another fluorochrome (eg Cy5). Both pools are mixed together with unlabelled blocking DNA, which blocks repetitive sequences in the genome. After denaturation, this mixture is hybridised to normal metaphase spreads, in the case of conventional CGH, or to an array of genomic clones, in the case of array-based CGH. After hybridisation, the fluorescence ratio of the two fluorochromes is measured along the axis of each chromosome in conventional CGH and for each arrayed clone in array-based CGH Software is used to segment the spots of the hybridised array and to calculate a background corrected log 2 ratio of the hybridised fluorochromes as well as other parameters that assess data quality. The log 2 ratio would then be a reflection of the relative DNA copy number between the two hybridised specimens for a certain arrayed element. Data are typically normalised so that the median log 2 ratio ¼ 0. The expected log 2 ratio of a single copy gain in a diploid genome, when hybridised versus normal genomic DNA, would be +0.58, while for a single copy loss this would be À1. In practice, log 2 ratios can range from -4 for homozygous deletions to log 2 ratio .6 for high-level amplifications ( Figure 2 ). 4, 5 The genomic resolution at which these aberrations can be detected is determined by three major factors: the genomic distance between the arrayed DNA elements; the size of the elements; and, if ratios are obtained by averaging data from neighbouring clones, then the number (and spacing) of the clones used will also affect the resolution. For example,
Albertson et al. showed that by arraying overlapping large insert clones, aberrations could be mapped with genomic resolution ($50 kb) that was less than the size of the clones ($150 kb). 6 In order for microarray CGH to be clinically useful as a diagnostic/prognostic tool, one needs a robust system with the sensitivity to quantitatively detect a wide spectrum of copy number changes, ranging from homozygous deletions and low-level DNA copy number aberrations to high-level amplifications. To achieve this level of sensitivity one needs a high signal-to-noise ratio resulting from high specific hybridisation and low background. The hybridisation signal intensity depends on many factors. One critical factor is the complexity (size) of the genome being analysed compared to the complexity (size) of the DNA sequences in the array spots. In general, for a given genome, the signal intensity increases as the complexity of the DNA in the spots is increased. Also, the properties of the DNA specimens interrogated by the array will affect the ratios. The purity Hybridisation signal intensity depends on the complexity of the genome being analysed and the complexity of the DNA sequence of the arrayed spots Figure 2 : Normalised DNA copy number ratios of clones on chromosomes 1 (a), 9 (b) and 8 (c) in three different cell lines. 5, 26 Clones are processed as described previously. 5 For each plot, the clones are sorted from the p-arm to the q-arm of the DNA appears to be particularly important as it affects the ability to label both the test and reference genome equivalently.
TECHNOLOGICAL APPROACHES TO ARRAY CGH
In the early implementations of array CGH, arrays were comprised of large insert genomic DNA clones such as bacterial artificial chromosomes (BACs) to which differentially labelled genomic DNA pools were hybridised in the presence of Cot-1 DNA. 4, 7 These large clones, containing $150 kb of genomic DNA inserts, provided sufficient signal intensity to quantitatively detect single copy number changes as well as homozygous deletions and high-level amplifications. By using BACs that contain a sequence tagged site (STS) and/ or have been end-or fully sequenced, one can map copy number changes directly onto the sequence of the human genome ( Figure 3) . Sets of STSs containing cytogenetically mapped BAC clones are currently available. 8 Since each arrayed element gives reliable data regarding DNA copy number, BAC arrays can be used to accurately and quantitatively map amplicons, which facilitate the identification of oncogenes. 6 Also, because of its accuracy in detecting lowlevel copy number aberrations, microarray CGH on arrays of BACs can be used in many medical genetic studies. 9 Disadvantages of this approach, however, are the fact that BACs are single copy vectors and that the yield of BAC DNA from a standard BAC preparation is low compared to standard plasmid preparations. In addition, accurately depositing sufficient quantities of whole BAC DNA can be problematic due to the viscosity of the printing solutions. This is caused by the high-molecular weight DNA. Reducing the size of the BACs by sonication significantly reduces viscosity and aids in reliably depositing BAC DNA on the substrate. 4, 10, 11 Also, chemical modification of BAC DNA prior to preparation of the DNA spotting solution has been described. 12 Although the treatments described above overcome difficulties with printing whole BAC DNA, issues regarding production of sufficient quantities of BAC 13 to amplify BAC DNA. 5 The DNA is cut with a frequently cutting restriction enzyme, after which primers are ligated and the ligated fragments are amplified using these primers. A second PCR, using a fraction of the first ligationmediated PCR, is performed, and this DNA is used for spotting. From one ligation-mediated PCR, multiple second PCRs can be performed providing large quantities of printing solutions. The use of a frequently cutting restriction enzyme and a high-fidelity DNA polymerase means that the BAC sequence appears to be largely maintained. Moreover, virtually identical DNA copy number ratios can be obtained by hybridising to the ligationmediated PCR representation or the whole BAC DNA. This technology has several advantages. The BAC sequence is well represented in the spotting solution and only small amounts of BAC DNA are required initially for the ligation-mediated PCR, which can then be used as template for 40-50 second PCRs, to make printing solutions. The BAC sequence will, however, be underrepresented in the spotting solution if a certain sequence is sparse in restriction enzyme recognition sites, such that the distance between two adjacent sites is greater than the maximum length that can be spanned by the highfidelity DNA polymerase. The use of a frequent cutting enzyme with a 4-base recognition site helps to reduce this problem.
Other methods use degenerate oligonucleotide primer PCR (DOP-PCR) to amplify BAC DNA.
14-17 As originally described, DOP-PCR uses a mixture of primers, each comprised of defined 39 and 59 sequences that flank a random hexanucleotide sequence. Low temperature annealing cycles are used initially to promote annealing at multiple sites by the primer mixture. There may, however, be a bias toward amplification of sequences corresponding to the 39 most hexanucleotide of the primer that are close together and in opposite direction. To increase the level of representation, Fiegler et al. designed three DOP primers. 17 The 59 sequences of these primers are identical to the 6MW DOP primer first described by Telenius et al.
14
The 39 sequences were designed such that human DNA would be amplified preferentially compared to Escherichia coli DNA, a known contaminant of DNA preparations from large insert clones. Three separate amplification reactions are carried out. A second PCR is performed using the first DOP-PCRs as a template, but in this reaction amplification is primed with an amine-linked primer in which the 39 end matches the 59 ends of the first round of DOP primers. Arrays produced by this approach provided reliable detection of low-level DNA copy number aberrations in a human cell line. Based on these promising first results, one expects that the method will prove to be robust and to have high dynamic range when applied to clinical samples or specimens containing homozygous deletions and/or high-level amplifications.
A third approach to performing CGH PCR-based methods may be used to generate large quantities of BAC DNA for printing, but must aim at maximising the representation of the BAC DNA sequence analysis uses microarrays comprised of mapped cDNA clones. 18 Microarrays containing thousands of cDNAs are widely available and have been used extensively to analyse gene expression levels at the mRNA level, by simultaneously hybridising differentially labelled mRNA pools. The use of cDNA arrays for CGH is appealing because of their widespread availability and because both DNA copy number and expression analysis of one sample can be performed in parallel on the same arrayed elements. Thus, one can readily compare DNA copy number and mRNA expression levels. 19, 20 Performing array CGH analysis on cDNA microarrays, however, poses technical challenges for reliable detection of single copy number changes in genomes of mammalian complexity. cDNA clones only represent on average 0.5-2 kb of intron lacking genomic sequence, resulting in greatly diminished signal intensities compared to hybridisation to BACs. As discussed earlier, a high signal-to-noise ratio is necessary to quantitatively and reliably detect low-level DNA copy changes on individual array elements and thus there is generally greater clone-to-clone ratio variation on cDNA arrays. To reduce the noise level when hybridising genomic DNA to cDNA clones, a moving average of ratios of several adjacent cDNA clones is used. 18 This procedure will reduce resolution but does not severely affect the resolution when arrays containing large numbers of cDNAs are used. In smaller genomes, such as yeast, cDNA and oligonucleotide arrays have provided useful data. 21 Amplification of fluorescent signals is often used in cytogenetic applications and thus might also be useful to augment the low signals obtained when CGH is carried out on cDNA arrays. Heiskanen et al. described tyramide-based amplification of signals obtained after hybridising genomic DNA to cDNA microarrays. 22 In this work, however, only DNA amplifications greater than 5-fold could reliably be detected, and the method did not allow two different DNAs to be distinguished simultaneously, so that it was necessary to hybridise the test and reference samples to two different microarrays. Thus, the utility of signal amplification methodologies is yet to be demonstrated for array CGH.
Compared to BAC arrays, cDNA microarrays appear to be an attractive format for array CGH, because: there is widespread access to arrays containing large numbers of mapped cDNA clones; cDNAs are easier to propagate for preparation of spotting DNA; and higher resolution mapping might be possible if reliable measurements were possible on single clones. Robustness and measurement capability for low-level DNA copy number changes appear to vary considerably between laboratories, however. Further development of this approach, and an understanding of the factors important for success, therefore seem necessary before cDNA arrays can be expected to provide the majority of practitioners with reliable detection of low-level DNA copy number changes, particularly when analysing nonhomogeneous or polyploid clinical samples.
Several CGH approaches have been developed that employ reducedcomplexity representation of the genomic DNAs as well as the array elements. Geschwind et al. used a PCR-based method in which arrays are comprised of inter-Alu PCR amplified and cloned fragments of genomic clones, such as cosmids or BACs. 23 Arrays are then hybridised with inter-Alu PCR amplified and labelled pools of specimen genomic DNA. Since the arrays are comprised of cloned DNA fragments, large quantities can relatively easily be produced by PCR. The use of inter-Alu PCR for the specimen genomic DNA allows one to use small amounts of genomic DNA, which is important in some applications.
Alternatively, Lucito et al. used arrays comprised of cloned human DNA restriction fragments and/or long oligonucleotides hybridised with reduced Detecting low-level DNA copy number aberrations on an cDNA microarray platform is challenging complexity representations of test and reference genomic DNA. 24, 25 The representations are prepared by digesting the genomic DNA with a restriction enzyme after which primers are annealed, ligated and then amplified by PCR using the primer sequences. Since amplification of smaller fragments is favoured in the reaction, the resulting amplified DNA is less complex than the starting sample. The PCR products are then labelled by random priming and processed for hybridisation. The arrays are made from individual sequences contained in the genomic representation. These sequences are either isolated and cloned, allowing preparation of DNA for array spots, or they are synthesised. By reducing the complexity of both genomic DNA and arrayed DNA, one can in principle improve the signal-to-noise ratio. In published applications of this technique, however, ratios were still obtained by averaging data from several spots. The main advantages of this approach are the requirement for only small amounts of input genomic DNA and the fact that large quantities of DNA spotting solutions can be obtained relatively easily. The main drawback, though, is the difficulty with which low-level DNA copy number aberrations can be detected. One should as well keep in mind that the use of PCR to amplify pools of genomic DNA for hybridisation might result in differential amplification of sequences in the test and reference genomic pools and thus affect ratios.
APPLICATIONS
Genome-wide array CGH can be used to map recurrent regions of copy number aberrations when analysing large numbers of tumour samples. 5 Subsequently, assembly of arrays with high-density clone coverage across a region allows further definition of recurrent aberrations. For example, Albertson et al. used array CGH to quantitatively and precisely map amplicon structures in tumours, which aided in the identification of oncogenes. 6 Additionally, because of its precision and sensitivity, the use of array CGH allows one not only to classify tumours based on their types and numbers of DNA copy number aberrations, it also allows one to ask specific questions about the underlying genetic defects that permit the selection for these aberrations. 26 Moreover, because many developmental abnormalities are characterised by the presence of low-level genomic imbalances, many of which result in DNA copy number alterations, array CGH can be used to detect the size and location of these aberrations and correlate them with the clinically observed phenotype. 9, 10 Veltman et al. described the use of array CGH for the detection of genomic aberrations in (sub)-telomeric regions, often deleted in mentally retarded patients. 16 Currently, these aberrations are detected in the clinical laboratory by fluorescent in situ hybridisation (FISH) assays with individual telomere probes. In the future, the throughput of such tests may be increased by applying array CGH to assay all telomeres simultaneously.
The array CGH format has also been applied together with other assays to profile epigenetic changes. For example, Zardo et al. used array CGH in combination with restriction landmark genomic scanning to assess both DNA copy number and methylation status in order to identify genes inactivated by single copy deletion and methylation of the remaining copy. 27 In an alternative approach, Shi et al. assembled arrays of CpG island clones and then hybridised bisulphite-treated tumour and normal DNA specimens to the arrays in order to reveal differences in the methylation status at these loci. 28 Other studies have used array CGH to map protein binding sites in the genome. 29, 30 In this technology, genomic DNA is immunoprecipitated using specific antibodies for DNAbinding proteins. By competitively hybridising two differentially labelled immunoprecipitated genomic DNA pools, one can identify protein-DNA binding regions in the genome and compare patterns of protein-DNA Array CGH is being applied to detect chromosomal imbalances in cancer and developmental abnormalities binding sites in, for example, tumour and normal DNA.
In conclusion, array CGH currently provides a reliable platform for the detection of DNA copy number changes for a wide variety of applications. More and more new applications are to be expected in both research and clinical settings.
